Cure8 research brief
Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the cohort studied.
Women with ulcerative colitis considering or using hormonal contraception; gastroenterologists and IBD clinicians advising patients on contraception; reproductive health providers.
This multicenter retrospective longitudinal cohort study examined whether hormonal contraception (HCT) after ulcerative colitis (UC) diagnosis was linked to more recurrent flares or greater inflammatory burden.
Among 225 women (58 exposed to HCT) followed a median of 5.3 years, HCT exposure was not associated with increased risk of recurrent flares (adjusted HR 0.93, 95% CI 0.62–1.40).
Longitudinal biomarker analysis showed slightly higher CRP during HCT-exposed months, but other markers (platelets, ESR, albumin, alpha-1-acid glycoprotein, fecal calprotectin) and cumulative inflammatory burden were comparable between exposure periods.
The authors did not identify HCT-related adverse events but note the modest number of exposed women limits detection of small or rare effects.
Interpretation and practical points The study suggests that, in this cohort, use of hormonal contraception after UC diagnosis was not linked to more frequent recurrent flares or a meaningful increase in overall inflammatory burden.
A modest rise in CRP was observed with HCT months, but it did not translate into higher cumulative inflammation or more flares in adjusted analyses. Limitations to
Findings come from a retrospective cohort with limited numbers of HCT-exposed patients; the modest CRP increase noted during exposed months did not correspond to higher flare risk or overall inflammatory burden. This does not rule out small increases in risk or rare adverse events.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
